Therapeutic Class Overview: Treating Refractory Hematological Malignancies - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Therapeutic Class Overview: Treating Refractory Hematological Malignancies

Description:

Research on Global Markets has announced the addition of “Therapeutic Class Overview: Treating Refractory Hematological Malignancies “research report to their offering. The report provides an overview of the approved therapies for rrmm, ndmm, aml, mds, unmet need and limitations of the current soc for relapsed and refractory pts. For more information visit: – PowerPoint PPT presentation

Number of Views:90

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Therapeutic Class Overview: Treating Refractory Hematological Malignancies


1
(No Transcript)
2
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Insights
  • Targeting unmet needs in the treatment of cancer
    or hematological malignancies through innovative
    drug development strategies have witnessed
    favorable outcomes
  • Over the past decade, Proteasome inhibitor,
    Velcade (bortezomib) and the immunomodulatory
    drugs - Thalomid (thalidomide) and Revlimid
    (lenalidomide) have become the cornerstone of
    treatment for patients with Multiple Myeloma (MM)
    resulting in improved survival
  • However, eventually all patients relapse and new
    treatment options for Relapsed/ Refractory
    Multiple Myeloma (RRMM) are required to further
    improve survival and quality of life of this
    group of patients

3
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Insights (Continued)
  • Two new drugs have successfully fulfilled this
    need - POMALYST/ IMNOVID (pomalidomide - POM) and
    Kyprolis (carfilzomib-CFZ)
  • A similar scenario is expected to unfold in the
    treatment of Recurrent/ Refractory MDS (RR-MDS,
    High-Risk MDS), and Relapsed/ Refractory AML (R/R
    AML)
  • Innovative approach to treating unmet need has
    been handsomely rewarded in the past through
    in-licensing or outright acquisition of the
    mature or nascent product or innovator company at
    a premium

4
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Coverage
  • Overview of the approved therapies for RRMM,
    NDMM, AML, MDS, unmet need and limitations of the
    current SOC for relapsed and refractory patients
  • Competition and commercial opportunity in
    pursuing these therapy areas
  • Comprehensive list of the early and late stage
    drugs in the clinic, their MoA and the companies
    developing them

5
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Table of Contents
  • Executive Summary
  • Disease Overview MDS and AML
  • Current Standard of Care MDS and AML
  • Unmet Need AML
  • Late-Stage pipeline Targeting High-Risk or R/R
    MDS AND R/R AML
  • Late-Stage pipeline Targeting 1st-line Lower Risk
    MD
  • Key Milestones of Drugs For RRMDS/RRAML in
    2014-2015
  • Launch Timeline and Commercial Opportunity of
    Late-Stage Pipeline (RR MDS and RR AML)
  • Drivers of MA/Licensing Deals in MDS/AML

6
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Details
  • Publish date Feb 22, 2014
  • Number of slides 43
  • Geographic coverage Global
  • Available format PDF, CD, Hardcopy
  • Price for Single User License USD 1,500
  • Price for Site License USD 3,003
  • Price for Global User License USD 4,503
  • Delivery Time Within 1 business day
  • Payment Modes Credit/Debit Card, RTGS/Wire
    Transfer, Google Wallet, PayPal

7
Interested in this report?
To view more details regarding this premium
market research report, Please click here
For further information, get in touch with us
E-mail support_at_researchonglobalmarkets.com Call
US 1 866 325 7446 UK 44 203 514 2363 Others
91 22 4098 7600
About Us Research on Global Markets is a leading
source for market research on various sectors
globally offering premium research content from
worldwide publishers of market research reports
Industry Segments Industry Segments Industry Segments
Automotive Transport Consumer goods Agriculture
Food and Beverage Energy and Utilities Public Sector
Manufacturing Construction Healthcare Media Entertainment
IT, Telecom Electronics Services Others
About PowerShow.com